Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2005 5
2006 3
2007 2
2008 3
2009 1
2010 2
2011 3
2012 2
2013 4
2014 4
2015 5
2016 6
2017 6
2018 13
2019 14
2020 12
2021 14
2022 20
2023 16
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Results by year

Filters applied: . Clear all
Page 1
Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial.
Chen Y, Du CY, Shen S, Zhang W, Shan Y, Lyu A, Wu J, Shang C, Luo X, Wei J, Xiao H, Qiu J, Hua Y, Wang S, Wang T, Dai S, Zhang S, Xie B, Wu Y, Hao C. Chen Y, et al. Among authors: hao c. Clin Cancer Res. 2024 Apr 30. doi: 10.1158/1078-0432.CCR-24-0006. Online ahead of print. Clin Cancer Res. 2024. PMID: 38687583
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Llovet JM, et al. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. Lancet Oncol. 2023. PMID: 38039993 Clinical Trial.
Chinese expert consensus on the overall management of liver function in conversion therapy for liver cancer (2022 edition).
Meng Q, Yang Z, Zhu Z, Li J, Bi X, Chen X, Hao C, Huang Z, Li F, Li X, Li G, Yang Y, Zhang Y, Zhao H, Zhao H, Zhu X, Zhu J, Cai J; Liver Tumor Branch of the China International Exchange and Promotive Association for Medical and Healthcare (CPAM); Gastrointestinal Cancer Multidisciplinary Cooperation Group of Cancer Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College; Liver Cancer Professional Committee of Chinese Medical Doctor Association. Meng Q, et al. Among authors: hao c. Chin Med J (Engl). 2023 Dec 20;136(24):2909-2911. doi: 10.1097/CM9.0000000000002950. Epub 2023 Nov 27. Chin Med J (Engl). 2023. PMID: 38018217 Free PMC article. No abstract available.
Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer.
Qin S, Li J, Bai Y, Wang Z, Chen Z, Xu R, Xu J, Zhang H, Chen J, Yuan Y, Liu T, Yang L, Zhong H, Chen D, Shen L, Hao C, Fu D, Cheng Y, Yang J, Wang Q, Qin B, Pan H, Zhang J, Bai X, Zheng Q. Qin S, et al. Among authors: hao c. J Clin Oncol. 2023 Nov 20;41(33):5163-5173. doi: 10.1200/JCO.22.02630. Epub 2023 Aug 30. J Clin Oncol. 2023. PMID: 37647576 Clinical Trial.
124 results